Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,491 across all filing types
Latest filing 2020-09-30 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
JOINT ANNOUNCEMENT - INSIDE INFORMATION / DISPOSAL OF 20% INTEREST IN THE MACAU CHINESE BANK LIMITED / RESUMPTION OF TRADING
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a major transaction involving the disposal of a 20% interest in The Macau Chinese Bank Limited (MCB) by Lippo Limited and Hongkong Chinese Limited (HKC). It includes specifics about the transaction, parties involved, consideration, regulatory implications under the Listing Rules, and resumption of trading. The document references compliance with Listing Rules Chapter 14, which governs major transactions, and includes financial details and strategic rationale for the disposal. It is not a full financial report, audit report, or earnings release, but rather a formal announcement of a significant corporate transaction. Therefore, the document fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset disposals.
2020-09-30 English
JOINT ANNOUNCEMENT - TRADING HALT
Regulatory Filings Classification · 95% confidence The document is a joint announcement by Lippo Limited and Hongkong Chinese Limited regarding a trading halt on their shares pending the release of a joint announcement related to a major transaction. The text explicitly states that trading is halted pending a major transaction announcement, which is inside information. There is no detailed financial data, no report attached or referenced as published, and no certification or voting results. The document is an announcement about a trading halt due to an upcoming major transaction announcement, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories like M&A filings or capital updates yet.
2020-09-30 English
EXCHANGE NOTICE - TRADING HALT
Regulatory Filings Classification · 95% confidence The document is a short notice from the Hong Kong Stock Exchange regarding a trading halt for Hongkong Chinese Limited. It does not contain financial statements, management reports, or specific corporate actions like dividends or M&A, but rather serves as a general regulatory announcement regarding market activity. As it does not fit into the specific categories provided, it falls under the RNS (Regulatory Filings) category.
2020-09-30 English
CHANGE OF FINANCIAL YEAR END DATE
Regulatory Filings Classification · 95% confidence The document is an announcement from Hongkong Chinese Limited regarding a change in the company's financial year end date from 31 March to 31 December. It includes details about the reasons for the change, the impact on subsequent financial reporting periods, and deadlines for future financial results publication. The document is relatively short (3543 characters) and serves as a formal notification to shareholders and the market about this change. It does not contain actual financial statements or detailed financial data, nor is it a full report. It is an official announcement related to a change in financial reporting periods, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories like Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-09-18 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE IND APPLICATION FOR BEVACIZUMAB BIOSIMILAR IN MAINLAND CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the acceptance of an IND (Investigational New Drug) application for a bevacizumab biosimilar in Mainland China. It includes a press release with details about the regulatory acceptance, clinical study results, market data, and company background. There are no financial statements, detailed financial performance data, or comprehensive report content typical of Annual Reports (10-K), Interim Reports (IR), or Earnings Releases (ER). The document is not a regulatory filing in the sense of officer certifications or compliance documents, nor is it a report publication announcement since it contains substantive information rather than just a notice of report availability. It is clearly an announcement of a regulatory milestone related to drug development and market progress, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories like Capital/Financing Update or Legal Proceedings. The document length (6270 characters) and content support this classification with high confidence.
2020-09-14 English
CONNECTED TRANSACTION GRANT OF AWARDED SHARES UNDER SPECIFIC MANDATE TO A CONNECTED PERSON PURSUANT TO THE SHARE AWARD SCHEME
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the grant of awarded shares under a specific mandate to a connected person pursuant to a share award scheme. It details the terms of the grant, the connected transaction implications under the Hong Kong Listing Rules, the upcoming Extraordinary General Meeting (EGM) to approve the grant and mandate, and related corporate governance and regulatory compliance information. The document is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about a share award transaction and related shareholder meeting. It fits the category of a Regulatory Filing (RNS) as it is a formal announcement required by the stock exchange and listing rules, providing detailed information about a connected transaction and upcoming shareholder approval, but it is not a report or presentation itself.
2020-09-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.